25 mg/m2 as 1 hr IV infusion every 3 wk in combination w/ oral prednisone 10 mg daily. Dose modification: Reduce dose to 20 mg/m2 if patient experiences adverse reactions. Premed at least 30 min prior to each dose: Dexchlorpheniramine 5 mg or diphenhydramine 25 mg or equiv antihistamine; dexamethasone 8 mg or equiv steroid; ranitidine 50 mg or equiv H2 antagonist.
Hypersensitivity. Discontinue in severe hypersensitivity; serious GI toxicity. Not to be administered in patients w/ neutrophils ≤1,500/mm3. Febrile or prolonged (>1 wk) neutropenia. Patients at risk of developing GI complications eg, neutropenia, history of pelvic RT, GI ulceration & bleeding. Monitor CBC on wkly basis during cycle 1 & before each treatment cycle thereafter. Consider primary prophylaxis w/ granulocyte colony stimulating factor in patients w/ high-risk clinical features; rehydration, anti-diarrheal or anti-emetic medications. Not to be mixed w/ any other drugs. May affect ability to drive & use machines. Renal failure. Not to be given in patients w/ hepatic impairment (total bilirubin, ≥ULN, or AST &/or ALT ≥1.5x ULN). Women of childbearing potential should avoid becoming pregnant during treatment. Pregnancy & lactation. Ped patients. Elderly ≥65 yr.
Sign Out
